The treatment combined SCINTIX biology-guided radiotherapy with “conventional” stereotactic body radiotherapy to simultaneously target the patient’s lung tumor and a solid tumor located in another area of the body, according to a Sept. 5 news release shared with Becker’s. The hospital is part of Yale New Haven Health.
SCINTIX radiotherapy uses positron emission tomography data and reacts to a lung or bone tumor’s motion during treatment, allowing radiation to be delivered more precisely. At the same time, stereotactic body radiotherapy can target a solid tumor in a different location.
The multi-target treatment is delivered in five fractions or fewer, the release said.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
